Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Dermatol. 2003 Jan;148(1):142-6.

Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial.

Author information

  • 1Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Université Paris VI, 47-83 boulevard de l'Hôpital, France. olivier.chosidow@psl.ap-hop-paris.fr

Abstract

BACKGROUND:

Randomized clinical trials of valaciclovir in recurrent herpes labialis are lacking.

OBJECTIVES:

To determine whether a single course of valaciclovir, i.e. 500, 1000 or 2000 mg, administered during the prodrome of herpes facialis, could be beneficial.

METHODS:

Three hundred and forty-five out-patients with herpes labialis were screened and randomized for a multicentre, double-blind clinical trial. Ninety-six patients had no recurrence after 6 months of follow-up; 249 patients were finally included in the intent-to-treat (ITT) population. The main outcome measure was the rate of aborted episodes at day 3. The three treatment groups were similar at baseline.

RESULTS:

There was no statistically significant difference between the groups in rates of aborted lesions at day 3 in the ITT population, in particular between the 500 mg and 2000 mg treatment groups.

CONCLUSIONS:

Although a placebo group was not included in this pilot study, a single dose of valaciclovir was not considered beneficial in patients with recurrent herpes facialis.

PMID:
12534609
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center